News
IVA
3.330
-3.48%
-0.120
Weekly Report: what happened at IVA last week (0408-0412)?
Weekly Report · 4d ago
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.
Seeking Alpha · 04/09 14:03
Inventiva Is Maintained at Buy by Canaccord Genuity
Dow Jones · 04/08 11:54
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
TipRanks · 04/08 11:30
Weekly Report: what happened at IVA last week (0401-0405)?
Weekly Report · 04/08 10:46
Inventiva’s Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor Earnings
TipRanks · 04/04 06:00
Weekly Report: what happened at IVA last week (0325-0329)?
Weekly Report · 04/01 10:44
Buy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical Trials
TipRanks · 04/01 10:25
Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)
TipRanks · 03/28 14:10
Inventiva SA ADR Announces Optimistic 2023 Results
TipRanks · 03/27 21:30
Inventiva GAAP EPS of -€2.43, revenue of €17.48M
Seeking Alpha · 03/27 20:06
Inventiva FY23 €(2.43) Vs €(1.31) YoY; Revenues For 2023 Amounted To €17.5 Million, Up By 43.4%, Compared To €12.2 Million In 2022
As of December 31, 2023, the Company's cash and cash equivalents amounted to €26.9 million. R&D expenses for 2023 were up 82% compared to 2022. Lanifibranor's revenues for the full year of 2023 amounted to 43%. The Company is actively reviewing potential financing options.
Benzinga · 03/27 20:03
Weekly Report: what happened at IVA last week (0318-0322)?
Weekly Report · 03/25 10:47
Inventiva Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
Dow Jones · 03/20 12:28
Promising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH Treatment
TipRanks · 03/20 12:25
HC Wainwright & Co. Reiterates Buy on Inventiva, Maintains $22 Price Target
Benzinga · 03/20 12:17
Inventiva’s Lanifibranor Shows Promise in NASH and T2D Treatment: A Buy Rating Justified
TipRanks · 03/19 17:25
Analysts’ Top Healthcare Picks: Inventiva (IVA), Tenaya Therapeutics (TNYA)
Inventiva (IVA) and Tenaya Therapeutics (TNYA) have 2 analysts maintaining Buy ratings on the Healthcare sector. Inventiva has an analyst consensus of Strong Buy with an average price target of $18.25. Tenaya has a Strong Buy consensus of $14.67, which is a 197.6% upside from current levels.
TipRanks · 03/19 10:40
Inventiva Phase 2 study for MASH drug meets primary endpoint
Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.
Seeking Alpha · 03/18 21:45
Inventiva’s LEGEND Trial Shows Promising Results
TipRanks · 03/18 21:27
More
Webull provides a variety of real-time IVA stock news. You can receive the latest news about Inventiva S.A. through multiple platforms. This information may help you make smarter investment decisions.
About IVA
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.